What is Advanced Oncotherapy?
Advanced Oncotherapy is a pioneering medical technology firm specializing in the development of particle therapy systems designed to improve cancer treatment outcomes. At the core of its innovation is the Linac Image Guided Hadron Technology (LIGHT), a proprietary proton accelerator that significantly reduces the physical footprint and capital expenditure required for traditional proton therapy. By delivering proton beams with superior precision and electronic control, the company aims to provide healthcare providers with a cost-effective alternative to legacy systems, ultimately reducing treatment-related side effects for patients. The firm maintains a strategic focus on Geneva-based engineering excellence, ensuring that its technology remains at the forefront of modern oncology.
How much funding has Advanced Oncotherapy raised?
Advanced Oncotherapy has raised a total of $23.3M across 5 funding rounds:
Multiple Rounds
$13.3M
Share Placement
$10M
Debt (2017): $3.7M with participation from Blackfinch Investments
Debt (2017): $2.6M led by Blackfinch Investment.
Debt (2017): $1.9M supported by Blackfinch Investment.
Debt (2017): $5.1M, investors not publicly disclosed
Share Placement (2020): $10M backed by SI Capital Ltd
Key Investors in Advanced Oncotherapy
Blackfinch Investments
An investment firm focused on providing capital to growth-stage companies across various sectors, including technology and healthcare.
SI Capital Ltd
A financial services firm specializing in corporate finance and strategic share placements for emerging growth companies.
Undisclosed Investor
An institutional participant providing capital to support the development of advanced medical technology systems.
What's next for Advanced Oncotherapy?
With the recent infusion of capital, Advanced Oncotherapy is expected to prioritize the commercial rollout and operational scaling of its LIGHT accelerator technology. The strategic roadmap likely involves strengthening manufacturing capabilities and expanding clinical partnerships to integrate these compact systems into existing healthcare facilities. As the company moves deeper into its enterprise-level growth phase, the focus will shift toward market penetration and the long-term validation of its proton therapy efficacy. Investors will be monitoring the firm's ability to maintain its competitive advantage in the medical device market while navigating the complex regulatory and logistical requirements of global healthcare infrastructure deployment.
See full Advanced Oncotherapy company page
